Our Tools

Conflicts of Interest Map

A system-level view of potential industry influence on patient care. The published manuscript is available at BMJ. More details on our methods can be found here.
The Takeaways
Revealing the complex network of Conflicts of Interest
Conflicts of interest (COI) related to pharmaceutical, medical device, and biotechnology companies are common and potentially influence patient care. Our interactive, evidence-based map encapsulates all known ties, financial and non-financial, between the medical product industry and the healthcare ecosystem. The map also spotlights the scarcity of critical safeguards like COI oversight and transparency. Click the different parts of the map below to explore how direct industry ties, extending via interrelationships among other parties and activities, often culminate at patient care.  
Download Image

Player Categories


Market Supply Chain

Medical Profession



How It Works

Click on the individual pathways, players, or activities to learn more.

How It Works

Click a circle to activate a pathway. You may activate multiple pathways at the same time. Hover over a pathway for more information.

Sources of Transparency !

Governing Policies !

Payers to Formulary Selection

Click a circle to activate a pathway. You may activate multiple pathways at the same time. Hover over a pathway for more information.

Financial Influences

Non-Financial Influences

Click here to reset.

Isolate Pathways & Regulations:

Click here to view the financial pathways.
Click here to view the non-financial pathways.
Click here to view sources of transparency.
Click here to view sources of transparency.

Access All of the Features

See more on the desktop version. Send an email reminder to yourself.
Request a Reminder

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Xeljanz, the FDA, and nine years of patient harm
Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action
Drug Pricing Lab 05/31/2022
Atypical antipsychotics: Decades of use, unfathomable harms
Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly
Drug Pricing Lab 05/31/2022
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Milliman 12/23/2021
Comparing Factors that Influence Pharmaceutical Pricing and Access in the…
Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.
Drug Pricing Lab 12/20/2021
Biosimilars in Medicare Part D: pricing dynamics and considerations
The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.
Milliman 12/14/2021
Evaluating Industry’s Drug Pricing Claims
A closer look at three of PhRMA’s most cited talking points.
Drug Pricing Lab 11/18/2021
Mapping conflict of interests: scoping review
A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.
Drug Pricing Lab 11/03/2021
Production Plus Profit Pricing (P-quad) FAQ
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020

Stay up to date on our work and news